Shanghai Juncell Therapeutics

This early-stage study is testing a new treatment for people with advanced liver or pancreatic cancers that have not responded to standard therapies. The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), which are taken from a tumor sample…

This early study tests a personalized cell therapy for people with advanced gastrointestinal cancers that have not responded to standard treatments. Doctors take immune cells from the patient's own tumor, grow them in a lab, and give them back through an IV. The goal is to see if…

This study tests a treatment called TIL therapy for people with advanced melanoma that hasn't responded to standard treatments. Doctors take immune cells from a patient's tumor, grow more of them in a lab, and put them back into the patient to help fight the cancer. The goal is t…

This early-stage study tests a new treatment called GC201 TIL for people with advanced gynecologic cancers that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are collected from their tumor, genetically modified to better fight ca…

This study tests a treatment using immune cells called TILs, taken from a patient's own tumor, grown in a lab, and given back through an IV. It is for people with advanced solid tumors who have not responded to standard treatments. The goal is to see if this therapy is safe and c…

This early-phase study tests a personalized cell therapy for people with brain glioma. Doctors take immune cells from the patient's tumor, grow them in a lab, and give them back to the patient. The goal is to see if this treatment is safe and can shrink tumors. About 50 adults wh…

This early-stage trial tests a new treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. …

This study tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to attack the cancer. About 98 participants wi…

This early-stage study tests a treatment called TIL therapy for people with advanced breast cancer who have run out of standard options. Doctors take immune cells from a patient's tumor, grow them in a lab, and give them back after a short chemotherapy. The goal is to see if this…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better attack cancer. The trial enrolls 18 adults with advanced solid tumors (including breast, lung, and gastrointestinal cancers) who have not re…

This early-stage study tests a new treatment called GC203 TIL for people with pancreatic cancer that has not improved with standard therapies. The treatment uses a patient's own immune cells, which are collected from the tumor, modified in a lab to better fight cancer, and then g…

This early-phase study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. Doctors take immune cells from a patient's own tumor, grow them in a lab, and infuse them back into the patient. The goal is to see if this approach i…